Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Galena Biopharma Inc    GALE   US3632561086

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/15/2014 12/16/2014 12/17/2014 12/18/2014 12/19/2014 Date
1.63(c) 1.53(c) 1.63(c) 1.62(c) 1.57(c) Last
901 446 1 860 938 1 494 084 1 673 051 1 604 855 Volume
-3.55% -6.13% +6.54% -0.61% -3.09% Change
More quotes
Company
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.It currently develops peptide antigenbased off the shelf cancer immunotherapies for... 
Sector
Pharmaceuticals
Calendar
03/25Earnings Release
More about the company
Surperformance© ratings of Galena Biopharma Inc
Trading Rating : Investor Rating :
More Ratings
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | GALE | US3632561086 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 8,70 M
EBIT 2014 -53,2 M
Net income 2014 -44,5 M
Debt 2014 -
Yield 2014 -
Sales 2015 19,0 M
EBIT 2015 -40,4 M
Net income 2015 -40,0 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 21,9x
Capi. / Sales 2015 10,1x
Capitalization 191 M
More Financials
Latest news on GALENA BIOPHARMA INC
12/11 Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bon..
12/08 GALENA BIOPHARMA : Presents GALE-401 (Anagrelide Controlled Release) Clinical Tr..
12/05 GALENA BIOPHARMA : to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (n..
12/02 GALENA BIOPHARMA : Receives Notice of Allowance of U.S. Patent Application for G..
12/01 GALENA BIOPHARMA : Other Events (form 8-K)
12/01 GALENA BIOPHARMA : to Present GALE-401 (Anagrelide Controlled Release) Phase 1 C..
11/25 GALENA BIOPHARMA : to Present at the Oppenheimer 25th Annual Healthcare Conferen..
11/20 GALENA BIOPHARMA : Entry into a Material Definitive Agreement, Financial Stateme..
More news
Sector news
1d ago JAZZ PHARMACEUTICALS : Receives FDA Approval For Intravenous Administration Of E..
1d ago CUBIST PHARMACEUTICALS : FDA OKs Cubist antibiotic for serious infections
1d ago CUBIST PHARMACEUTICALS : Announces FDA Approval of New Antibiotic ZERBAXA™..
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF